迪哲醫藥(688192.SH):舒沃哲最新研究成果獲選2024年美國臨牀腫瘤學會大會報吿
格隆匯5月24日丨迪哲醫藥(688192.SH)公佈,公司將在2024年5月31日—6月4日於芝加哥舉行的美國臨牀腫瘤學會(ASCO)年會上,公佈其自主研發的I類新型肺癌靶向藥舒沃哲(通用名:舒沃替尼片)針對表皮生長因子受體(EGFR)20號外顯子插入(Exon20ins)突變型晚期非小細胞肺癌(NSCLC)的兩項最新研究成果。其中舒沃哲?針對經治EGFRExon20ins突變型NSCLC的全球註冊臨牀研究“悟空1B部分”(WU-KONG1PartB)數據將在本次大會以口頭報吿形式首次公佈。初步分析結果表明,研究已達到其預設的主要研究終點,舒沃哲二/後線治療EGFRExon20ins突變NSCLC展現出積極的抗腫瘤療效,且安全性良好。另一項針對接受舒沃哲治療的EGFRExon20ins突變型NSCLC患者血漿循環腫瘤DNA(ctDNA)最新生物標誌物探索研究也將做大會報吿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.